Showing results (711-720 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|January 8, 2010
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinomaRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Molecular Cancer Therapeutics|January 8, 2010
Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor modelsSherif Daouti, Brian Higgins, Kenneth Kolinsky, et al.
Molecular Cancer Therapeutics|January 8, 2010
Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesisSrinivas Koduru, Raj Kumar, Sowmyalakshmi Srinivasan, et al.
Molecular Cancer Therapeutics|January 8, 2010
Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTDTarek Shalaby, André O von Bueren, Marie-Louise Hürlimann, et al.
Molecular Cancer Therapeutics|August 24, 2016
Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2Alexey V Danilov, Shanhu Hu, Bernardo Orr, et al.
Molecular Cancer Therapeutics|August 24, 2016
TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced DiarrheaHannah R Wardill, Joanne M Bowen, Ysabella Z A Van Sebille, et al.
Molecular Cancer Therapeutics|May 4, 2018
A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize SignalingMonique J Kauke, Alison W Tisdale, Ryan L Kelly, et al.
Molecular Cancer Therapeutics|April 15, 2018
Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAsMaire F Osborn, Andrew H Coles, Diane Golebiowski, et al.
Molecular Cancer Therapeutics|April 15, 2018
Clinical Next-Generation Sequencing for Precision Oncology in Rare CancersRoman Groisberg, David S Hong, Jason Roszik, et al.
Molecular Cancer Therapeutics|April 15, 2018
RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK BlockadeBruno Bockorny, Maria Rusan, Wankun Chen, et al.
Pageof 599